Shares of Silo Pharma, Inc. (SILO) are surging more than 50% Friday morning after the company reported positive data for its drug candidate SPU-21 for the treatment of Arthritis.
The company today announced positive interim data from its dose optimization study of SPU-21 joint homing peptides for subcutaneous administration of anti-arthritic agents.
Silo Pharma said it is pursuing a development plan utilizing its liposomal joint homing peptides as a potential therapy for rheumatoid arthritis (RA).
SILO, currently at $5.21, has traded in the range of $0.17-$12.45 in the last 1 year.
Source: Read Full Article
Lates News:
-
Coinbase Reaches $100 Mln Settlement With NYDFS For Failures In Compliance
-
$BTC Surges Above $26,400 Level Thanks to U.S. CPI Data That Suggests the Fed Could Pivot Soon
-
Markets Nervous As Debt Limit Deadlock Persists
-
CureVac Rallies On Positive Data From Its COVID-19, Flu Vaccine Candidates
-
Cryptos Rise; Bitcoin Touches 3-week High